Skip to main content
. 2021 Mar 18;8(1):e000856. doi: 10.1136/bmjresp-2020-000856

Figure 3.

Figure 3

(A) Change from baseline in ACQ-7 score with IND/GLY/MF versus IND/MF and SAL/FLU at week 26 and (B) proportion of patients achieving MCID in ACQ-7 score with IND/GLY/MF versus IND/MF and SAL/FLU at week 26 (full analysis set). IND/GLY/MF medium-dose, IND/GLY/MF 150/50/80 µg one time per day; IND/GLY/MF high-dose, IND/GLY/MF 150/50/160 µg one time per day; IND/MF medium-dose, IND/MF 150/160 µg one time per day; IND/MF high-dose, IND/MF 150/320 µg one time per day; SAL/FLU high-dose, SAL/FLU 50/500 µg two times per day. Data presented as LS mean±SE, error bars represent SE values. Δ, LS mean treatment difference; ACQ, Asthma Control Questionnaire; IND/GLY/MF, indacaterol acetate/glycopyrronium bromide/mometasone furoate; IND/MF, indacaterol acetate/mometasone furoate; LS, least squares; SAL/FLU, salmeterol xinafoate/fluticasone propionate.